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The extraordinary pace of research on coronavirus dis-
ease 2019 (COVID-19) has been one of the major suc-
cess stories of the pandemic. Therapeutic trials involving 
thousands of patients, which usually take years to com-
plete, have been reported in a matter of months. National 
and international registries and networks have reported 
on tens of thousands of patients in near real time. How-
ever, there have also been many challenges: hundreds of 
trials have been underpowered, duplicated, or of poor 
quality; excessive bureaucracy has complicated study ini-
tiation; and only a small percentage of eligible patients 
worldwide have been enrolled in studies, while many 
others have been treated with off-label, unproven thera-
pies. All of this has been complicated by an “infodemic” 
of low-quality medical information, accelerated by social 
media. The goal of the present article is to discuss the 
challenges, achievements, and future directions of critical 
care research during the pandemic (Table 1).
Early studies of COVID-19 patients, whether observa-
tional or interventional, involved small numbers of sub-
jects and incomplete outcome data. This lack of scale, 
along with abbreviated follow-up, produced poor quality, 
inconsistent data. Early intensive care unit (ICU) mortal-
ity estimates, for example, ranged from 0 to 85% [1].
Large-scale studies of critically ill COVID-19 patients, 
based on national or international registries, have pro-
duced better quality data, allowing greater understanding 
of the influence of patient-level and system-based factors 
on the incidence and outcome of severe COVID-19 [2, 
3]. Unfortunately, many countries lack ICU registries and 
many existing registries do not include key data points 
that are relevant to emerging infectious diseases.
The International Severe Acute Respiratory and 
Emerging Infection Consortium (ISARIC) was created 
in 2012 to overcome barriers to the study of emerging 
infectious diseases through the creation of protocols and 
case report forms (CRFs) that could be rapidly adapted 
to new outbreaks [4]. To date, ISARIC has reported data 
on over 200,000 hospitalized COVID-19 patients in 
more than 40 countries [5]. Differences in datasets across 
studies remain a challenge, however, and integrating a 
minimal dataset into national registries would facilitate 
demographic studies and between-country comparisons. 
The use of registry-embedded clinical trials is a strategy 
that facilitates trial enrollment and management, thus 
increasing study participation.
Agility is a key element for successful COVID-19 thera-
peutic studies. The use of platform trials has facilitated 
testing of multiple treatments in parallel and increasing 
the efficiency of the search for effective interventions [6], 
while adaptive designs have allowed for the introduc-
tion of new therapies into ongoing studies along with 
the removal of unsuccessful therapies after meeting pre-
specified stopping rules. These strategies have enabled 
trials such as the Randomised Evaluation of COVID-19 
Therapy (RECOVERY) [7], the Randomized, Embed-
ded, Multifactorial Adaptive Platform for Community-
acquired Pneumonia (REMAP-CAP) [8], and the World 
Health Organization SOLIDARITY trial [9] to generate 
high-quality data on multiple therapeutic options within 
the first year of the pandemic. These studies are opera-
tional in several countries including LMICs. Platform 
trials are complex and require careful planning and sta-
tistical oversight. However, the benefits in generating 
high-quality data in a low-cost and efficient way during a 
pandemic are clear [10].
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COVID-19 studies have embraced pragmatic designs 
that reduce the burden of participation. These include 
open-label medications, shortened CRFs and/or auto-
mated data collection, and a focus on therapies with 
pre-existing regulatory approval, reducing the level of 
regulatory oversight. This pragmatic approach has ena-
bled hospitals without extensive research experience to 
participate, thereby maximizing patient recruitment.
In spite of these efforts, COVID-19 study involve-
ment, particularly in low- and middle-income coun-
tries, remains poor. The COALIZÃO trials in Brazil [11, 
12] have circumvented some of these challenges using 
a pre-existing research network and pragmatic study 
design. However, there remains a significant discrep-
ancy between trial participation in high-income and low-
income countries. This is not only a question of research 
equity and generalizability of results, but also of safety, as 
a lack of clinical trial access may increase the likelihood 
of off-label medication use [13, 14].
Leadership that prioritizes and supports high-quality 
clinical research has been a key ingredient in success-
ful pandemic research, and it has a role in encouraging 
the population to participate in trials. The RECOVERY 
trial in the UK, supported by the National Health Service 
(NHS), enrolled over 10,000 patients at 176 hospitals in 
3 months [7]. Similarly, the WHO has promoted partici-
pation in clinical trials, such as its SOLIDARITY Trial, 
which is now recruiting in over 500 hospitals worldwide 
[15].
Leadership is also required in setting research priori-
ties. Many overlapping (and often underpowered) trials 
have taken place worldwide. To avoid wasted time and 
effort, funding agencies and scientific societies should 
prioritize funding of large-scale trials that are likely to 
produce definitive results and encourage collaboration 
between investigators with similar interests.
Agile randomised controlled trials (RCTs) are only pos-
sible if a fast, albeit rigorous, process of ethics approval 
is in place. National or regional Research Ethics Boards 
(REBs) can greatly simplify this process by allowing a 
single centralized approval for multiple sites. In the UK, 
for example, a single REB approval is valid for the entire 
country. Regulatory issues are particularly challenging for 
international studies.
In the current pandemic, we have been fighting not 
only a disease but an infodemic, which has been greatly 
amplified by social media [16]. Additionally, data have 
Table 1 Demographics and baseline characteristics (open-label safety analysis set)
What went wrong? Solutions
Small observational studies with highly variable results Creation of national or international registries with harmonized data collection 
for emerging disease outbreaks that are operational both during and outside 
pandemic periods
Absence of observational data from outside traditional academic 
or research centres
Creation of national or international registries that collect data from all hospitals 
within a given jurisdiction
Few observational studies from low- and middle-income countries Implementation of national electronic medical record systems in low and middle-
income countries to allow for easy (or automated) data collection.
National audits or registries for critical illness
Too many small clinical trials with inconclusive results Avoidance of single centre and single region therapeutic trials
Creation of national or regional ethics review boards
Coordinated data collection between clinical trial networks
Prioritization of large scale multicentre studies as well as collaborations between 
investigators with overlapping interests
Medical societies to encourage clinical trial participation in place of off-label 
therapy use
Too many overlapping/competing clinical trials Collaboration across clinical trial networks and funding agencies to ensure fewer, 
large-scale studies are funded or that small studies work together to generate 
larger datasets
Prioritization of adaptive platform trials that enable parallel testing of multiple 
therapeutic options
Bureaucratic delays in setting up clinical trials Fast-track approvals for pandemic-related clinical trials
Creation of national or regional ethics review boards
Few therapeutic trials in low- and middle-income countries Inclusion of low and middle-income countries in international multi-centre clinical 
trials
Creation of clinical trial networks that include both high- and low-income coun-
tries
Simplification of data collection forms
Simplification of trial protocols
Simplification of regulatory requirements for trials using already approved medica-
tions
been rushed into the public domain through the publica-
tion of preprints and press releases [16]. In the absence 
of complete and verified data, medical professionals are 
left uncertain as to how to care for their patients. In July 
2020, for example, Gilead issued a press release report-
ing a 62% mortality benefit for remdesivir based on an 
unpublished retrospective comparison, an astonishing 
result which was not confirmed by subsequent RCTs [9].
Although peer-review slows the pace of publishing, 
it is a fundamental step to the production of high-qual-
ity data. Peer-review does not eliminate poor-quality 
research, as shown by the publication of uncontrolled 
studies of hydroxychloroquine and azithromycin, 
amongst others. Nor does it eliminate potential fraud, as 
shown by the publication (and retraction) of the Surgi-
sphere dataset. However, medical journals have a vested 
interest in publishing accurate data and, when an article 
is called into question, investigating and retracting if nec-
essary. The scientific and medical communities must lead 
by example and wait for the publication of high-quality 
peer-reviewed data prior to making decisions about 
potential therapies [17].
During COVID-19 pandemic, agility, pre-existing 
infrastructure, platform trials, adaptive design, prag-
matic design, and centralized REB approvals contributed 
to successful research outcomes. Worldwide, however, 
only a small percentage of hospitals and patients are 
participating in COVID-19 research and there remains 
enormous untapped potential, particularly in low- and 
middle-income countries. Clinicians and health systems 
must adopt the mentality that efficient and systematic 
research participation is an integral part of pandemic 
response, and that every patient not given the opportu-
nity to participate in a study represents a valuable oppor-
tunity lost [18].
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